Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Women Benefit from Immunotherapy as Much as Men

Women Benefit from Immunotherapy as Much as Men

JAMA Oncology reported a systematic review and meta-analysis by Wallis and colleagues, finding for advanced tumors, immune checkpoint inhibitor treatment provided no difference in overall survival benefit between men and women. An earlier study suggested men benefited more, but methodological problems in previous analyses prompted this larger investigation.

This meta-analysis included, through late 2018, studies in advanced solid (organ) cancer evaluating immunotherapy in 23 randomized clinical trials . All trials had overall survival data stratified by sex. Trials comparing immunotherapy regimens were excluded.

- What Is a Meta-Analysis? Meta-analyses are the broadest studies, combining results from multiple independent studies on a subject and statistically analyzing the findings. Their results constitute the strongest scientific evidence.

Comparing Immunotherapy’s Survival Benefits

The 23 studies in the meta-analysis included 9322 men (% 67,9) and 4399 women (% 32,1), mostly in their 70s. Compared with standard treatments, immunotherapy reduced death risk by %25 in men and %23 in women; these values were not statistically different.

Subgroup analyses also found no significant sex difference according to organ of origin, line of treatment, immunotherapy class, methodology, or proportion of women in the study group.

In conclusion , these analyses showed no statistically significant association between immunotherapy effectiveness in advanced cancer and patient sex: women benefit from immune checkpoint inhibitor immunotherapies as much as men.

Sources

Christopher J. D. Wallis, MD, PhD ve ark.
Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers
A Systematic Review and Meta-analysis.
JAMA Oncology, 3 January 2019.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Women Benefit from Immunotherapy as Much as Men

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy